Resumo

TAMAYO-ALONSO, Pilar et al. Evolution of radioiodine treatment in differentiated thyroid carcinoma. Rev. ORL [online]. 2022, vol.13, n.2, pp.97-109.  Epub 21-Nov-2022. ISSN 2444-7986.  https://dx.doi.org/10.14201/orl.28343.

March 2021 has marked the eightieth anniversary of targeted radionuclide therapy, recognizing the first use of radioactive iodine (RAI) to treat thyroid disease by Dr. Saul Hertz on March 31, 1941. Success with hyperthyroidism fueled a seamless, almost intuitive transition to the use of RAI in thyroid carcinoma and marked the beginning of a new paradigm for thyroid cancer diagnosis and management. Since then, several therapeutic strategies have been adopted in the management of patients with differentiated thyroid cancer (DTC) and there are still controversies today regarding which patients with DTC should be administered RAI and what RAI activity should be administered, issues that will be commented in this review.

Palavras-chave : differentiated thyroid cancer; radioactive iodine; ¹³¹I; therapy; indications; controversies.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )